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Virus demyelination
John K Fazakerley and Robert Walker
Centre for Infectious Diseases, University of Edinburgh, Summerhall, Edinburgh, United Kingdom
A number of viruses can initiate central nervous system (CNS) diseases that
include demyelination as a major feature of neuropathology. In humans, the
most prominent demyelinating diseases are progressive multifocal leukoen-
cephalopathy, caused by JC papovirus destruction of oligodendrocytes, and
subacute sclerosing panencephalitis, an invariably fatal childhood disease
caused by persistent measles virus. The most common neurological disease of
young adults in the developed world, multiple sclerosis, is also characterized
by lesions of inflammatory demyelination; however, the etiology of this disease
remains an enigma. A viral etiology is possible, because most demyelinating
diseases of known etiology in both man and animals are viral. Understanding
of the pathogenesis of virus-induced demyelination derives for the most part
from the study of animal models. Studies with neurotropic strains of mouse
hepatitis virus, Theiler’s virus, and Semliki Forest virus have been at the fore-
front of this research. These models demonstrate how viruses enter the brain,
spread, persist, and interact with immune responses. Common features are an
ability to infect and persist in glial cells, generation of predominantly CD8+
responses, which control and clear the early phase of virus replication but
which fail to eradicate the infection, and lesions of inflammatory demyelina-
tion. In most cases demyelination is to a limited extent the result of direct
virus destruction of oligodendrocytes, but for the most part is the consequence
of immune and inflammatory responses. These models illustrate the roles of
age and genetic susceptibility and establish the concept that persistent CNS
infection can lead to the generation of CNS autoimmune responses. Journal of
NeuroVirology (2003) 9, 148–164.
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Introduction
There are clear examples of demyelinating diseases
in humans and animals that are not associated with
virus infections, for example adrenoleukodystrophy
or demyelination associated with vitamin deficiency
or toxins. However, many naturally occurring cen-
tral nervous system (CNS) demyelinating diseases
of known etiology, in man and animals, are viral
in origin. Of the human demyelinating diseases, the
most prominent is multiple sclerosis (MS). This is the
most common neurological disease of young adults in
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the developed world; however, the etiology remains
to be determined. For some demyelinating diseases,
viruses are clearly the etiologic agent and infect the
CNS, JC papovavirus (JCV) leading progressive mul-
tifocal leukoencephalopathy (PML) is an example.
In other demyelinating diseases, for example postin-
fectious encephalomyelitis, also known as postvacci-
nal or perivenous encephalomyelitis, demyelination
is preceded by a systemic virus infection but there
is no, or only rarely, evidence of direct virus infec-
tion of the CNS. This has been observed with rabies,
measles, mumps, rubella, influenza, vaccinia, and
smallpox virus infections and vaccinations (Johnson,
1998). This demyelination is generally considered to
be autoimmune.
The relative inaccessibility and sensitivity of the
CNS precludes studies on disease pathogenesis in
humans and much of the knowledge on infections
and immune responses in this system has been de-
rived from experimental animal models. For studies
on mechanisms of viral demyelination, prominent
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Table 1 Demyelinating viruses
Virus Family Host
Semliki Forest Virus Togaviridae Mouse
Ross River virus Mouse
Venezuelan equine Mouse
encephalitis virus
Mouse hepatitis virus Coronaviridae Mouse, rat, non-
human primates
Herpes simplex I virus Herpesviridae Mouse, man
Measles Paramyxovirus Rodents
Canine distemper virus Dog
JC virus Papovaviridae Man
Theiler’s virus Picornaviridae Mouse
Maedi-visna virus Retroviridae Sheep
HTLV-I Man
HIV Man
Vesicular stomatitis virus Rhabdoviridae Mouse
Chandipura virus Mouse
experimental systems include Theiler’s virus, mouse
hepatitis virus, and Semliki Forest virus infections
of laboratory rodents. Also valuable have been ex-
perimental studies of natural infections of animals
that induce demyelination, these include maedi-
visna virus in sheep and canine distemper virus
in dogs. Studies on human brain samples from
cases of PML, subacute sclerosing panencephalitis
(SSPE) and human T-cell lymphotropic virus type I
(HTLV-I)–associated myelopathy (HAM), caused by
JCV, measles virus, and HTLV-I, respectively, have
also proved of great value in understanding events
and mechanisms in CNS demyelination, though
the picture of neuropathology they present is most
frequently that of end-stage disease. Table 1 pro-
vides a list of viruses associated with demyelinating
diseases.
It should be realized that many viruses infect
the nervous system without producing demyelina-
tion. These include viruses that produce acute or
subacute encephalitis, for example rabies virus and
viruses that produce widespread and even life-long
persistent infections, for example lymphocytic chori-
omeningitis virus. Tropism of infection is probably
relevant here. There is considerable variation in the
cell types infected by different neurotropic viruses,
some are highly specific in the cell types infected,
others infect several cell types. Rabies predominantly
infects neurons, HIV microglial cells, and JC virus
oligodendrocytes, but Theiler’s virus and Herpes
simplex virus can infect neurons, oligodendrocytes,
astrocytes, and microglial cells. Many neurotropic
viruses not associated with demyelinating diseases
produce minimal infection in oligodendrocytes.
In both human and animals, most natural cases of
demyelinating disease associated with virus infec-
tion are complications that occur only rarely, rela-
tive to the extent of infection. JC virus infects and
persists in most adults but PML is a rare disease.
Measles virus infection generally results in a sys-
temic infection characterized by skin rash but in rare
cases results in neurologic disease, measles inclusion
body encephalitis (MIBE) in young adults, or SSPE in
children. Visna, a demyelinating disease of sheep, is
far less common than the pulmonary disease maedi
caused by the same virus, maedi-visna virus. Canine
distemper is rare relative to the extent of infection of
the dog population. Postinfectious encephalomyeli-
tis is a rare disease relative to the extent of the in-
fection and vaccination. Experimental studies with
the related Theiler’s virus, which is also generally
an enteric infection but which does cause CNS de-
myelinating disease in mice, indicate that only 1 in
every 2000 naturally infected mice develops neuro-
logic disease.
One explanation for the low incidence of demyeli-
nating disease following virus infections would be
a low efficiency of neuroinvasion. Certainly, viruses
differ in their ability to enter the CNS. Rabies virus,
one of the most deadly of viruses, always gains en-
try to the CNS after a peripheral infection. This
is well-documented to be by travel along periph-
eral nerves (Murphy, 1977). The other main route
of entry to the CNS is via the blood and here too
some viruses can be highly efficient, for example
the alphaviruses Semliki Forest virus, Sindbis virus,
and Venezuelan equine encephalitis. Although it is
tempting to extrapolate and assume that incidence
of clinical disease is a measure of the frequency of
neuroinvasion, this seems unlikely to be the case.
Determining the extent of correlation between CNS
infection and clinical disease is difficult. Assay of
virus load in the brain following experimental ex-
traneural inoculation of rodents indicates that it is
possible for viruses to be highly efficient at neu-
roinvasion but to produce apparent clinical disease
only rarely. The incidence of SSPE in nonimmu-
nized populations has been estimated to be approxi-
mately one case per million children per year (Detels
et al, 1973); however, it is possible that measles
virus is more efficiently neuroinvasive than this sug-
gests. In a study of 59 patients with acute uncom-
plicated measles, without any neurologic signs, 30%
had a pleocytosis shortly after onset of rash, 15%
had viral-specific antibodies in their cerebrospinal
fluid, 10% had evidence of blood-brain barrier dis-
turbance, and 50% had abnormal electroencephalo-
grams (Hanninen et al, 1980). Neuroinvasion, at least
by some viruses, may therefore be more frequent than
neurologic clinical disease would suggest.
Progressive multifocal leukoencephalopathy
PML is a fatal CNS demyelinating disease of humans,
most frequently associated with immunosuppression
and caused by infection and destruction of oligoden-
drocytes by JCV. The virus is ubiquitous and found
worldwide. Human infection is usually acquired in
the first decade of life and 80% to 90% of adults are
seropositive. An asymptomatic persistent infection
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occurs in kidney, lymphoid tissue, and CNS. Virus is
shed into the urine, one study detected JCV DNA–
positive urine in 40% of Caucasian adults in the
United States (Agostini et al, 1997). In the major-
ity of individuals, infection is kept under control by
immune responses, though there is evidence that a
more productive but asymptomatic infection occurs
in some individuals, perhaps with mild disturbances
to immune surveillance. PML is most frequently as-
sociated with leukemia, lymphoma, and particularly
with immunosuppression.
PML has increased in significance over the last
20 years in parallel with the acquired immuno-
deficiency syndrome (AIDS) epidemic. Around 5%
of AIDS patients develop PML and this accounts
for an estimated 85% of all PML cases (Berger and
Concha, 1995; Power et al, 2000). The combination
generally results in a short survival time. JCV is de-
tectable in peripheral blood in around 50% of human
immunodeficiency virus (HIV)-seropositive individ-
uals (Tornatore et al, 1992). Several studies have de-
tected JCV DNA by polymerase chain reaction (PCR)
in the brains of ‘normal’ individuals, that is, individ-
uals without PML or HIV infection, with a frequency
ranging from 12% to 50% (White et al, 1992; Elsner
and Dorries, 1992; Ferrante et al, 1995; Gibson et al,
1993). However, these PCR-based studies have in-
evitably used human postmortem brain material and
the extent to which positives represent infection of
brain cells versus infection of leukocytes in the cere-
bral vascular has not been established. At present, it
is unclear whether immunosuppression allows virus
replication in the periphery with subsequent spread
to the brain or whether JCV is generally present in
the brain and immune responses lose control of this
infection upon immunosuppression. In the case of
PML in association with AIDS, there is also the is-
sue of whether HIV activates JCV (Tada et al, 1990;
Schmidbauer et al, 1990).
Clinically, PML has an insidious onset with demen-
tia, weakness, visual disturbances, and sometimes
ataxia. Disease is generally rapidly progressive. Neu-
ropathology is characterized by both small foci and
large areas of demyelination in several brain areas,
including the cerebrum, brain stem, and cerebellum.
Lesions are most frequently periventricular and oc-
cur at grey, white matter junctions. Large lesions are
visible upon gross anatomical observation, can be
necrotic, and contain few intact axons. Within small
lesions, or around the edge of larger lesions, oligo-
dendrocytes are enlarged and contain characteristic
intranuclear inclusions. Electron microscopy demon-
strates papovavirus particles in these nuclei and was
the basis for the original association between PML
and JCV (ZuRhein and Chou, 1965). These intranu-
clear crystalline arrays of virus are the basis for the in-
tranuclear inclusions. The extent of mononuclear cell
infiltration is variable. A prominent inflammatory re-
sponse is often absent. However, plasma cells are gen-
erally present and numbers correlate with magnitude
of intrathecal oligoclonal immunoglobulin G (IgG)
reactive to the viral VP1 protein (Weber et al, 1997).
Studies of immune responses in blood cells indi-
cate an impairment of Th-1 immune responses, with
presence of JCV-specific cytotoxic T lymphocytes,
suggesting a more favorable prognosis (Weber et al,
2001). Demyelination in PML is generally accepted
to result from direct destruction of virus infected
oligodendrocytes (Astrom et al, 1958; Walker, 1978;
Johnson, 1983).
Subacute sclerosing panencephalitis
SSPE is a human inflammatory demyelinating CNS
disease that occurs several years after initial measles
virus infection. It is predominantly a disease of chil-
dren, with a prevalence of 1 in 100,000 to 1 in
1 million infected children. Measles infection at an
early age, <2 years, is a risk factor (Modlin et al,
1977). The disease has an insidious onset with be-
havioral changes, mental deterioration, myoclonus,
ataxia, and sometimes seizures and visual distur-
bances. Progress is variable, remissions may occur,
but death usually results within 1 to 3 years. Serum
and cerebrospinal fluid (CSF) have high or very high
titers of measles virus antibodies (Connolly et al,
1967; Tourtellotte et al, 1968). Neurons and glial
cells have cytoplasmic and nuclear inclusion bod-
ies, immunostain for measles virus antigens, and con-
tain paramyxovirus virions by electronmicroscopy
(Bouteille et al, 1965; Jenis et al, 1973). Measles virus
can be recovered from SSPE brains. Virus-infected
cells can be widely distributed and most brain ar-
eas, with the possible exception of the cerebellum,
can be infected. Neuropathology varies according to
the duration of illness before death, though a picture
of events can be constructed. Infiltrating mononu-
clear cells are first apparent in the meninges and
perivascular cuffs and infiltrates can become exten-
sive. There is activation of astrocytes and microglial
cells, neuronophagia, and neuronal loss. Apopto-
sis has been observed both in infected and appar-
ently uninfected neurons, oligodendrocytes, and mi-
croglial cells (McQuaid et al, 1997). Some infected
neurons and oligodendrocytes contain fibrillary tan-
gles similar to those seen in neurodegenerative dis-
eases (McQuaid et al, 1994; Ikeda et al, 1995). Ul-
trastructurally, there have been many descriptions of
virally infected neurons and oligodendrocytes, but
there is general agreement that infected cells show no
evidence of budding virus (Iwasaki and Koprowski,
1974; Dubois-Dalcq et al, 1974; Paula-Barbosa and
Cruz, 1981; Schneider-Schaulies et al, 1995).
The events between initial measles virus infec-
tion and development at a later date, generally 6 to
8 years later, of SSPE are not clear. During acute in-
fection, measles virus is present in leukocytes and
these cells are also virus positive in SSPE (Fournier
et al, 1985), but it is unclear how or when CNS
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infection is established. CSF, electroencephalograms,
and nuclear magnetic imaging (MRI) studies during
acute measles virus infection suggest that this virus
is more efficiently neuroinvasive (»30%) than clini-
cal signs would suggest (Hanninen et al, 1980). Con-
sistent with this, measles virus RNA has been de-
tected in ‘normal’ human brain samples (Greenham
et al, 1988). It is also unclear whether virus that in-
fects the CNS is genetically identical to extraneural
virus or whether neuroinvasion and/or development
of disease requires generation and selection of spe-
cific genotypes. Analysis of measles virus sequences
from SSPE brain samples indicates that, relative to
reference strains, many genomes have mutations or
deletions (Baczko et al, 1986; Cattaneo et al, 1988).
Expression of the viral envelope proteins M, F, and
H is generally low or undetectable during persistent
infection, whereas expression of the nucleocapsid (N)
and phosphoprotein (P), which are components of the
ribonucleocapsid and required for RNA replication,
are always observed (Baczko et al, 1986; Liebert et al,
1986; Cattaneo et al, 1987). In common with other
paramyxoviruses, measles virus demonstrates an at-
tenuation of gene transcription from 30 to 50 along
the genomic RNA in all cell types. This gradient is
exaggerated in infected CNS cells, resulting in min-
imal transcription of 50 genes (Schneider-Schaulies
et al, 1989, 1995). Inhibition of translation of virus
transcripts in some cell types has also been de-
scribed (Schneider-Schaulies et al, 1989, Ogura et al,
1987, 1988; Miller and Carrigan, 1982; Yoshikawa
and Yamanouchi, 1984). Interferon responses may be
important and Mx protein is expressed in areas of
infection in SSPE brains (Schneider-Schaulies et al,
1994, 1999).
There is a vigorous immune response in SSPE,
with high levels of intrathecal virus-specific anti-
body, an intense mononuclear cell inflammatory re-
sponse that includes CD4C and CD8C T cells, plasma
cells, and macrophages, and proinflammatory cy-
tokines (Nagano et al, 1991; Hofman et al, 1991). The
antibody response is oligoclonal (Ebers et al, 1979;
Hall et al, 1979). In vitro, the antibody is neutraliz-
ing and capable of complement-mediated lysis of in-
fected human brain cells. Antibody can also decrease
cell surface expression of viral glycoproteins on cul-
tured cells and this has been suggested to contribute
to the establishment of persistence in vivo (Joseph
and Oldstone, 1975; Fujinami and Oldstone, 1980).
Addition of neutralizing antibodies to persistently in-
fected neural cells can down-regulate viral transcrip-
tion (Barrett et al, 1985; Schneider-Schaulies et al,
1992). SSPE patients have no apparent immunologi-
cal deficits (Mehta et al, 1994), nevertheless the im-
mune responses generated are clearly unable to clear
the persistent CNS infection; they may even be per-
petuating it.
Understanding the exact mechanism of persistence
and neuropathogenesis of measles virus infection
and SSPE has been hampered by the lack of animal
models. Natural virus isolates do not replicate in ro-
dents, though rodent-adapted strains have been stud-
ied. In infected rat CNS cells, as observed in vitro, an-
tibody enhances attenuation of transcription (Liebert
et al, 1990). In mice, an active cellular immune sys-
tem, particularly CD4C T cells, is important in the
control of infection and can lead to resistance to
encephalitis (Finke and Liebert, 1994; Finke et al,
1995; Urbanska et al, 1997). Two measles virus re-
ceptors have now been discovered, CD46 and CD150
(Naniche et al, 1993; Dorig et al, 1993; Tatsuo et al,
2000). CD46 transgenic mice have been generated and
the course of CNS infection studied (Rall et al, 1997;
Oldstone et al, 1999; Manchester and Rall, 2001;
Patterson et al, 2001). Virus replicates predominantly
in neurons; there is no attenuation of transcription
but as in SSPE, there is little or no virus budding. Un-
fortunately, infection of oligodendrocytes is rare and
there is no report that these mice develop lesions of
demyelination.
In summary, the exact mechanism of demyelina-
tion in SSPE remains unclear. However, it is clear
that virus infects and replicates in a restricted way
in both neurons and oligodendrocytes, there are var-
ious mutations in the genomes of persistent viruses,
there is loss of both cell types, and there is a strong
immune response.
Mouse hepatitis virus (MHV)
In mice and rats, strains of MHV (Coronaviridae)
cause a spectrum of disease from hepatitis and en-
teritis to encephalomyelitis and demyelination. MHV
can infect and produce demyelination in the brain of
nonhuman primates (Murray et al, 1992b). Human
coronaviruses, related to MHV, have been detected
in lesions of demyelination in MS brains (Murray
et al, 1992a; Stewart et al, 1992). Neurotropic strains
of MHV include MHV-4, MHV-JHM, and MHV-A59.
These viruses are relatively virulent and demyelina-
tion is seen only in survivors of acute encephalitis.
These animals often demonstrate hind limb paral-
ysis and are sometimes tetraplegic. Modulation of
infection and increased numbers of survivors can
be obtained by passive administration of antisera
(Buchmeier et al, 1984). However, a number of atten-
uated viruses, derived from these strains by mutage-
nesis or immune selection and maintain the ability to
induce demyelinating disease, have been much stud-
ied to dissect the pathogenesis of this infection.
MHV strains are not efficiently neuroinvasive and
neuropathology is generally studied following intrac-
erebral inoculation, though intranasal inoculation is
also an effective route of CNS infection (Pearce et al,
1994; Perlman et al, 1989). Differential ability in
early replication and spread correlates with virulence
(Fazakerley et al, 1992). Virulent strains are generally
first observed in neurons, whereas avirulent strains
infect neurons to a lesser extent. All strains infect
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ependymal cells, astrocytes, oligodendrocytes, and
microglia (Lavi et al, 1987; Sun and Perlman, 1995;
Stohlman et al, 1995a). Virulent viruses target several
brain areas but infection of and damage to structures
in the limbic and olfactory systems is common (Lavi
et al, 1986, 1990; Fazakerley et al, 1992; Sun and
Perlman, 1995). Tracking of virus through olfactory
system pathways is observed following intranasal
inoculation (Lavi et al, 1986; Perlman et al, 1989;
Pearce et al, 1994; Lane et al, 1997). Spread of the
virus is along neural pathways (Perlman et al, 1989;
Fazakerley et al, 1992). The virus envelope spike
glycoprotein S is a major determinant of virulence,
demonstrates great variability, and is responsible for
virus binding and entry. One receptor for the virus is
biliary glycoprotein 1a, a member of the carcinoem-
bryonic antigen family; other members of this family
may also function as receptors (Williams et al, 1991;
Dveksler et al, 1991; Chen et al, 1995). SJL mice have
a polymorphism of this gene, which renders them
resistant to widespread MHV infection (Dveksler
et al, 1993). Antibodies, CD4C and CD8C T cells
can each provide protective responses (Buchmeier
et al, 1984; Stohlman et al, 1986; Yamaguchi et al,
1991). Differences in immune responses are impor-
tant in determining the outcome of infection. For ex-
ample, following MHV-JHM infection, BN rats have
small nodular plaques of CNS demyelination and
remain clinically healthy, whereas Lewis rats have
large areas of white matter inflammation and develop
acute encephalitis or subacute demyelinating disease
(Watanabe et al, 1987). In BN rats, spread of infection
is controlled by a local antibody response and the
characteristically small lesions contain many plasma
cells. In Lewis rats, plasma cells are rarely observed
and a strong cell-mediated immune response devel-
ops, giving rise to large areas of white matter inflam-
mation (Dorries et al, 1987).
In mice surviving intracerebral inoculation, infec-
tious virus is generally detectable in the CNS for at
least the first week but is undetectable by 2 weeks.
Virus clearance is mediated principally by CD8C T
lymphocytes, but this is not a sterile immunity and
virus can persist (Stohlman et al, 1995a). Perforin-
mediated cytotoxicity controls infection of astrocytes
and microglia, whereas interferon-° controls infec-
tion of oligodendrocytes (Lin et al, 1998b; Parra et al,
1999). This dichotomy is interesting as major histo-
compatability complex (MHC)-I is expressed on each
of these cell types (Redwine et al, 2001). Antibody
responses are crucial in controlling spread of virus
(Ramakrishna et al, 2002). Persistence of viral RNA
and protein has been observed, mostly in glial cells
including oligodendrocytes, for up to a year post in-
fection (Knobler et al, 1982; Lavi et al, 1984; Perlman
and Ries, 1987; Adami et al, 1995; Parra et al, 1999;
Fleming et al, 1995). Analysis of virus RNA dur-
ing persistence indicates that many viral genomes
have mutations, particularly point and deletion mu-
tations in the S and N genes (Adami et al, 1995).
These genomes could be defective and unable to gen-
erate infectious virus. Persistence of a genotype with
changes in a defined CD8 T-cell epitope have also
been observed, consistent with selection of immune
escape variants (Pewe et al, 1996).
Demyelination is a feature of the neuropathology in
mice surviving infection with virulent strains as well
as in mice infected with avirulent strains. Follow-
ing inoculation of mice with MHV 2.2v-1, infection
of oligodendrocytes and demyelination are observed
within the first week (Wang et al, 1992). Demyeli-
nation increases over the following 2 weeks and is
followed by a period of remyelination and repair.
However, while this is ongoing, new focal lesions
are initiated (Erlich et al, 1987). Most studies de-
scribe demyelination concomitant with or following
clearance of virus infectivity and lesions have been
described months post infection (Woyciechowska
et al, 1984; Haspel et al, 1978; Stohlman and Weiner,
1981; Herndon et al, 1975; Erlich et al, 1987).
Demyelinating lesions are predominantly primary
demyelination with axonal sparing and are generally
inflammatory with scattered lymphocytes and lipid
containing macrophages (Lavi et al, 1986; Lampert
et al, 1973; Stohlman and Weiner, 1981). Demyelina-
tion is generally followed by remyelination, which
can be seen first a few weeks after onset of demyelina-
tion (Takahashi et al, 1987; Kristensson and Norrby,
1986; Herndon et al, 1977).
That demyelination is sometimes observed as early
as the first week post infection, when virus titers are
high, might suggest a direct viral pathology. In the
Lewis rat, early after infection, death of JHM-infected
oligodendrocytes is necrotic, whereas death of ap-
parently uninfected oligodendrocytes and oligoden-
drocyte death in the chronic phase of disease after
virus clearance is apoptotic (Barac-Latas et al, 1997).
This could be consistent with an early direct viral
effect and a later bystander effect mediated by in-
flammatory responses. Whereas there may be some
early direct viral destruction of oligodendrocytes, de-
myelination is described as absent, rare, or reduced
in SCID, RAG1, or immunosuppressed mice, indicat-
ing that a large element of the demyelination requires
immune or inflammatory responses. SCID mice nei-
ther clear infectious brain virus nor display large
lesions of demyelination, whereas athymic nu/nu
mice fail to clear virus but do have lesions of de-
myelination (Houtman and Fleming, 1996). RAG1-
null mice have been described to have no (Wu et al,
2000), small (Wu and Perlman, 1999) or moderate
(Matthews et al, 2002) lesions of demyelination. In
the case of RAG1-null mice with no demyelination,
transfer of CD4C or CD8C T cell–enriched lympho-
cyte populations resulted in demyelination, with
greater macrophage infiltration into CNS lesions and
greater clinical disease following CD4C cell trans-
fer, but greater spinal cord demyelination follow-
ing CD8C cell transfer, suggesting that CD4C and
CD8C T cells are both capable of mediating lesions
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of demyelination (Wu et al, 2000; Wu and Perlman,
1999). Consistent with this, other studies demon-
strate that neither CD4C nor CD8C T cells alone are
required for demyelination because lesions develop
in mice deficient in fl-2-microglobulin, MHC class
II, CD4, or CD8 or in mice depleted of CD8C T cells
(Houtman and Fleming, 1996; Gombold et al, 1995;
Lavi et al, 1995, 1999; Lane et al, 2000). Depletion
of CXCL10 (IP-10) or RANTES reduces inflammation
and demyelination (Lane et al, 1998, 2000; Liu et al,
2001). These chemokines probably mediate their ef-
fect by recruiting T cells and macrophages. However,
depletion of blood macrophages does not reduce de-
myelination (Xue et al, 1999). CXCL10 suppression
of inflammation early after infection also delays CNS
virus clearance and increases mortality (Liu et al,
2000). However, neutralization of CXCL10 in mice
with established demyelinating disease inhibits pro-
gression of demyelination, increases remyelination,
and improves neurologic function (Liu et al, 2001).
Neither perforin, Fas, tumor necrosis factor (TNFfi),
interleukin (IL)-10, interferon-° , nor immunoglobu-
lin are required for demyelination (Lin et al, 1997,
1998a; Parra et al, 1999, 2000; Stohlman et al, 1995b;
Matthews et al, 2002). In rats, JHM infection gener-
ates autoreactive T cells capable of mediating brain
inflammation on adoptive transfer (Watanabe et al,
1983). Whether these contribute to the pathology or
are also present in mice remains unclear. In humans,
T-cell lines cross-reacting with myelin basic protein
and human coronavirus 229E could be established
from some (4/16) multiple sclerosis patients but not
controls (Talbot et al, 1996).
In summary, the MHV model system demonstrates
that despite an active immune response, virus is
able to persist in glial cells, predominantly astrocytes
but including oligodendrocytes. Persistence is asso-
ciated with changes in the virus genome, possibly
resulting in defective virus or virus that escapes im-
mune surveillance. Persistence results in lesions of
demyelination. Some demyelination may be due to
direct virus infection and destruction of oligoden-
drocytes, but the majority is dependent upon specific
immune and inflammatory responses.
Theiler’s murine encephalomyelitis
virus (TMEV)
TMEV (Picornaviridae) was first isolated from mice
presenting with a flaccid paralysis of the hind limbs
(Theiler, 1934). TMEV is a natural enteric pathogen
of mice that is transmitted by the feco-oral route.
Based on differing biological characteristics, strains
of TMEV are generally divided into two subgroups.
Following intracerebral inoculation, the neuroviru-
lent GDVII and FA strains rapidly infect neurons and
induce an acute and usually fatal encephalomyeli-
tis. The second group, known as Theiler’s original
(TO), includes the BeAn, DA, WW, and Yale strains
and causes a biphasic disease in some strains of
mice (Lipton, 1975). During the first phase, lasting
for approximately 2 weeks, virus preferentially in-
fects neurons within the gray matter areas of the brain
and spinal cord and disease may present clinically
with a transient hind limb paralysis. By 3 weeks
post infection, despite clearance of virus from the
initial infected gray matter areas, the second phase
of disease occurs. This is characterized by persis-
tent and long-lasting infection of cells within the
white matter of the spinal cord accompanied by
chronic inflammation and demyelination. Virus per-
sistence is necessary for inducing the demyelinating
disease and determinants influencing susceptibility
or resistance to demyelinating disease are polygenic.
The strongest genetic influence involves the immune
response genes conferred by the MHC H-2 haplo-
types, in particular H-2D (Rodriguez and David, 1985;
Clatch et al, 1985; Azoulay-Cayla et al, 2001). Other
susceptibility loci include Tmevd-1 on chromosome
6, which maps close to genes coding for the T-cell re-
ceptor (TCR) fl chain (Melvold et al, 1987), Tmevd-2
on chromosome 3 (Melvold et al, 1990), and a locus
mapping close to the Ifng locus on chromosome 10
(Bureau et al, 1993).
That resistance to persistent infection is domi-
nantly associated with MHC class I genes suggests
that CD8C T cells are important determinants of virus
persistence and demyelination. Depletion of CD8C T
cells or infection of fl2-microglobulin–deficient mice,
on a resistant background, results in impaired abil-
ity to clear virus and development of demyelinat-
ing disease (Borrow et al, 1992; Fiette et al, 1993;
Pullen et al, 1993; Rodriguez et al, 1993). Generation
of a strong virus-specific CD8C cytotoxic T lympho-
cyte (CTL) response early in infection may confer
resistance to subsequent development of demyeli-
nating disease. Splenocytes from resistant C57BL/6
mice mount a faster and stronger anti-TMEV CTL re-
sponse than splenocytes from susceptible SJL/J mice
(Dethlefs et al, 1997). However, a recent study demon-
strated within the CNS of TMEV-infected SJL/J mice
CD8C T cells against a dominant VP3 virus capsid epi-
tope (Kang et al, 2002). These were H-2Ks restricted
and although H-2K molecules can present viral pep-
tides to CTL in susceptible SJL/J mice, a low level of
H-2K expression on cells within the CNS or a prefer-
ential expression of H-2Ds (Altintas et al, 1993) may
result in inefficient antigen presentation and dimin-
ished CTL reactivity.
Although the role of CD8C T cells in the first phase
of the biphasic disease appears critical in controlling
infection, their role in promoting demyelination is
controversial. In mice deficient in fl2-microglobulin
(Fiette et al, 1993) or perforin (Palma et al, 2001;
Rossi et al, 1998), susceptibility to demyelinating dis-
ease is exacerbated, suggesting no requirement for
CD8C T cells. However, other studies suggest that de-
spite increased demyelination in fl2-microglobulin–
deficient mice (Rodriguez et al, 1993), CD8C T cells
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are necessary for the perforin-dependent develop-
ment of neurologic deficits (Murray et al, 1998), as
demyelination alone is insufficient to cause clinical
symptoms (Rivera-Quinones et al, 1998). Yet, other
studies demonstrate that mice depleted of CD8C
T cells present with aggravated demyelination, en-
hanced inflammatory Th-1 cell responses, and earlier
onset of clinical disease (Begolka et al, 2001), sug-
gesting that CD8C T cells may be necessary to down-
regulate the proliferation of virus-specific CD4C
T-cell responses (Filaci et al, 2002).
Despite the ongoing presence of antiviral im-
mune responses in susceptible mouse strains, TMEV
can persist within the spinal cord for long periods
(Trottier et al, 2002). Within the spinal cords of per-
sistently infected mice, several studies suggest that
macrophages harbor the greatest viral load (Lipton
et al, 1995; Bihl et al, 1997) and to a lesser extent
glial cells (Brahic et al, 1981), including astrocytes
(Aubert et al, 1987) and oligodendrocytes (Rodriguez
et al, 1983; Simas and Fazakerley, 1996). A recent
study using brain-derived primary cell cultures sug-
gests that high levels of virus antigen in microglia
may represent mainly phagocytosed virus particles
and that preferential replication in astrocytes and
oligodendrocytes may be the basis of virus persis-
tence (Zheng et al, 2001).
Initial damage to the myelin-producing oligoden-
drocytes may result from direct cytolysis of virally in-
fected cells. However, because most studies suggest
that only low numbers of oligodendrocytes are in-
fected, it is more likely that oligodendrocyte damage
results from exposure to immune responses. Many
studies strongly suggest that the demyelinating phase
of the disease is principally dependent upon the gen-
eration of anti-TMEV–specific class II restricted CD4C
T-cell responses (Clatch et al, 1987). Flow cytom-
etry studies indicate that the majority of activated
T cells infiltrating the CNS are CD4C (Pope et al,
1996). Depletion of CD4C T cells abrogates demyeli-
nation whereas transfer of TMEV-specific CD4C T
cells enhances disease (Borrow et al, 1992; Gerety
et al, 1994). Initial CD4C T-cell responses are virus
specific and particularly directed against an immun-
odominant VP2 epitope (Gerety et al, 1991); however,
subsequent T-cell responses against myelin compo-
nents, including proteolipid protein (PLP), are ob-
served 3 to 4 weeks after onset of clinical disease. As
disease progresses, “epitope spreading” is observed,
with additional delayed-type hypersensitivity (DTH)
responses to multiple myelin antigens, including
myelin basic protein (MBP) and myelin oligodendro-
cyte glycoprotein (MOG) (Miller et al, 1997; Katz-
Levy et al, 1999). Because T-cell reactivity to virus
develops in advance of T-cell reactivity to myelin epi-
topes, molecular mimicry seems unlikely. Whether or
not these later, anti-myelin responses are involved in
propagating the demyelinating disease or are a conse-
quence of it remains unclear. Induction of tolerance
to TMEV and CNS epitopes can inhibit subsequent
development of demyelinating disease (Karpus et al,
1995; Neville et al, 2002).
In summary, the TMEV model system demonstrates
how genetics can control susceptibility to a persis-
tent CNS virus and the importance of early, par-
ticularly CD8C T-lymphocyte, immune responses in
determining the balance between virus elimination
and persistence. It also establishes the important con-
cept that CNS virus persistence can generate an au-
toimmune response, though the relevance of this
to the pathogenesis of demyelination remains to be
determined.
Semliki Forest virus (SFV)
The most commonly studied strains of SFV (Togaviri-
dae) are L10, prototypes A7 and A7(74), which are
respectively virulent and avirulent in adult mice. A
major determinant of virulence resides in the nsP3
protein, a component of the viral replicase (Tuittila
et al, 2000). All SFV strains are virulent in neona-
tal and suckling mice by all routes of inoculation.
A number of viruses generated by mutagenesis have
also been studied; from the point of view of de-
myelinating disease, the most notable of these is
M9 (Barrett et al, 1980). SFV has the advantage
of being neuroinvasive as well as neurotropic, al-
lowing study of virus entry into the CNS and the
functioning of the blood-brain barrier. Following in-
traperitoneal infection, all strains replicate in mus-
cles and other tissues, giving rise to a plasma viremia
(Pusztai et al, 1971). Virus crosses the cerebral en-
dothelial cells to initiate perivascular infection of
CNS cells, predominantly neurons and oligodendro-
cytes (Fazakerley et al, 1993; Balluz et al, 1993). In
neonatal mice or adult mice infected with virulent
strains, virus spreads rapidly along neurites, giving
rise to a widespread infection that is lethal within a
few days. In contrast, in adult mice infected with avir-
ulent strains, once virus reaches the CNS, it remains
confined to small perivascular foci around the initial
sites of entry (Fazakerley et al, 1993). In the absence
of T-cell immunity, this pattern of scattered focal in-
fection persists, probably for life, with no clinically
apparent deficit (Fazakerley and Webb, 1987; Amor
et al, 1996).
SFV-induced CNS demyelinating disease has been
most studied following infection of adult mice with
the A7(74) strain of virus. Following intraperitoneal
infection of immunocompetent adult mice, infectious
virus is detectable in the brain by 24 h. Titers rise
thereafter but are rapidly reduced following the on-
set of immune responses. By infectivity assay, virus
is detectable in the brain for the first 8 days but vi-
ral RNA is detectable for longer periods by in situ
hybridization (Fazakerley et al, 1993). Reverse tran-
scriptase (RT)-PCR studies following M9 infection in-
dicate that viral RNA can be detected in the brain for
even long periods, >90 days (Donnelly et al, 1997),
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and following A7(74) infection, antibody-producing
plasma cells in the brain and intrathecal antiviral
antibody are detectable for months, suggesting per-
sistence of viral antigen (Parsons and Webb, 1984,
1989). Disturbance of the blood-brain barrier is appar-
ent between 4 and 10 days, allowing passage of serum
proteins, including immunoglobulins (Parsons and
Webb, 1982; SoiluHanninen et al, 1994). This leaky
barrier corresponds to the time of increasing inflam-
matory cell infiltration and reduction of brain virus
titers and could be related to the massive influx of
cells or cytokine-mediated effects. Cerebral endothe-
lial cells up-regulate adhesion molecule expression
and MHC-I expression is up-regulated on a con-
centric network of parenchymal cells with a den-
dritic morphology, most probably microglial cells,
around the foci of infection (SoiluHanninen et al,
1997; Morris et al, 1997). Pleocytosis is apparent
from 4 days and subsides by 9 days, but cell counts
in the cerebrospinal fluid do not return to normal
for weeks (Parsons and Webb, 1984). An intense
inflammatory response characterized by perivascu-
lar cuffing, with invading cells spreading into the
parenchyma, is apparent histologically from 3 days.
Demyelination is first apparent by luxol fast blue
staining of paraffin sections around 14 days post in-
fection (Figure 1), but small focal lesions are apparent
by electron microscopy at 10 days (Suckling et al,
1978; Kelly et al, 1982). In the optic nerve, there
are lesions of demyelination and changes in visually
evoked responses and axonal transport (Tremain and
Ikeda, 1983). These are features that also occur in MS.
No demyelination is apparent in SCID mice, athymic
mice, or mice depleted of CD8C T cells (Amor et al,
1996; Fazakerley et al, 1983; Subak-Sharpe et al,
1993). Whether CD8C T cells are required to directly
destroy, possibly by perforin- or Fas-mediated path-
Figure 1 A lesion of demyelination in the white matter of the
cerebellum 18 days after SFV A7(74) infection. Stained with
luxol fast blue and cresyl violet. M indicates normal myelin
and D the area of demyelination that is vacuolated and contains
inflammatory cells.
ways, virally infected oligodendrocytes or whether
they act via other mechanisms, such as release of
interferon-° remains to be studied.
In summary, the SFV model allows for the study
of the kinetics of a natural infection that is highly
neuroinvasive and is associated with changes in the
blood-brain barrier. Demyelination in SFV infection
is immune mediated and appears to result from a
CD8C T cell–mediated destruction of virally infected
oligodendrocytes, with little or no direct viral de-
struction of these cells. This model also demonstrates
changes in optic nerves similar to those seen in MS.
Consistent features and questions
Demyelination in PML seems simply to result from
virus infection and destruction of oligodendrocytes
in individuals where immune responses are no longer
able to control this common infection. The situa-
tion may be exacerbated by molecular interactions
between JCV and HIV in AIDS patients. In SSPE,
measles virus infects glial cells but cannot be elim-
inated from the brain despite strong immune re-
sponses. It is notable that measles virus persistence is
associated with restricted virus replication and that
budding virions cannot normally be seen. If there are
any common features in the rodent model systems,
they are that the virus can infect and persist in glial
cells, that immune responses develop but fail to erad-
icate the infection, that CD8C T cells are particularly
important in early virus clearance, that in the absence
of virus eradication, antibodies prevent further virus
spread, and that although demyelination may to a
limited extent be the result of direct virus destruction
of oligodendrocytes, it is for the most part the con-
sequence of immune and inflammatory responses.
On top of this can be built up further layers of vari-
ables that govern whether or not infection will lead
to demyelinating disease. The first is age, as many
neurotropic infections show age-related differences
(Fazakerley, 2001). The second is the nature of the in-
fection, the dose, and the strain of virus. Some viruses
are efficiently neuroinvasive whereas others are not.
With many viruses that can cause CNS disease, inva-
sion of the CNS may be dependent upon other aspects
of physiology, such as diet, stress, or intercurrent in-
fection, or this process may be stochastic. The timing
of neuroinvasion relative to development of immune
responses is important, and the virus, its strain, and
the level of immunity determines the extent of CNS
infection. A third individual variable is host genet-
ics, which determines the type and magnitude of im-
mune response and in turn governs susceptibility to
persistent infection and disease (Brahic and Bureau,
1998).
Further understanding is needed in all of the above
areas but perhaps particularly to the question why it
is that these and several other viruses are able to per-
sist in CNS cells. Certainly, many of the viruses that
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persist in the CNS do not readily persist in other organ
systems. In the examples discussed here, it is persis-
tence in glial cells that is crucial, but there are several
viruses that can persist in neurons. Is it something
about immune responses in the specialized environ-
ment of the CNS, perhaps an inability to eliminate
virus-infected cells or a switching off of immune re-
sponse at too early a time, or is it something funda-
mental about the relationship between viruses and
long-lived neural cells?
Restricted infection of neural cells is a feature of
SSPE, of measles, of SFV A7(74) and TMEV BeAn in
the mouse models described above, and also of lym-
phocytic choriomeningitis virus infection (Oldstone
and Buchmeier, 1982; DeLaTorre et al, 1993). The na-
ture of these persistent, restricted infections remains
unclear. One possibility is that individual cells are
infected for long periods of time, though most re-
sults could also be explained by a dynamic persis-
tence in which infection of an individual cell has
a given half-life and that with time viral material
is eliminated, with or without cell loss. Infection of
new cells could be initiated at a slow rate, possibly
in some cases by spread between cells without for-
mation of virus particles, as has been described for
measles virus (Lawrence et al, 2000). Whether there
is gradual cell loss remains unclear, as careful mea-
surements have not been done. The extent of neu-
ronal loss in the brains of mice infected with scrapie
was not appreciated until precise quantitation was
done (Jeffrey et al, 1995). So the extent of cell loss
with time remains unclear as does the nature of per-
sistence, which could be static, that is, fixed within
individual cells, or dynamic, with movement be-
tween cells. In these restricted infections, replication
at some level is blocked. This could be a permanent
or a temporary block and it could vary between cell
types or individual cells. A temporary block could
result from inhibitory factors, for example interfer-
ons, and remain until these drop below an effective
level. There is, for example, evidence of interferon-
activated responses in measles virus–infected areas
of SSPE brains (Schneider-Schaulies et al, 1999).
Alternatively, cellular factors could be required for
productive replication, perhaps produced rarely in
response to cell activation. A situation in which
infection is generally restricted but occasionally pro-
ductive could occur. Restricted infection could also
result from infection of cells with specific virus geno-
types that have lost the ability to undergo productive
infection in specific cell types. The genotypes of JCV,
measles, and MHV that persist in the brain are dif-
ferent to the original infecting viruses. It is generally
not clear whether these genetic changes are required
to establish persistence or are a consequence of per-
sistence. The latter seems most likely.
It is generally considered that upon infection, most
virus-infected cells initiate apoptosis as an altruistic
response to curtail virus spread. This makes evolu-
tionary sense in renewable cell populations but not in
the specialized, postmitotic environment of the CNS,
and it seems that virus-infected mature CNS cells are
more refractory to initiating apoptosis than cells in
other tissue systems (Allsopp and Fazakerley, 2000).
This relative resistance to apoptosis is probably one
major factor in allowing many viruses to persist in
CNS cells. Another major factor is the failure of im-
mune responses to establish sterile immunity. CD8C
T lymphocytes seem to be important in controlling
CNS virus infections at early time points and may
function by eliminating virus-infected cells. If these
are oligodendrocytes, this will contribute to the de-
myelination. Certainly, CD8C T cells seem to con-
tribute to demyelination in MHV and SFV infections
(Subak-Sharpe et al, 1993; Wu et al, 2000). Why early
immune responses do not progress to completely
eradicate the infection is not clear. At least in the case
of the Theiler’s virus, inability to clear the infection,
persistence, and subsequent demyelination are de-
termined by host genetics (Brahic and Bureau, 1998).
Perhaps in addition, cells with a restricted virus in-
fection are not targeted by immune responses, do not
provide signals sufficient for immune-mediated de-
struction, or do so only with time. In Theiler’s virus
and probably to an extent in MHV infections, this per-
sistence drives a chronic immune response leading to
release of toxic factors that mediate bystander dam-
age, loss of uninfected oligodendrocytes, and genera-
tion of lesions of demyelination. In the case of at least
Theiler’s virus, this damage eventually leads to the
release of CNS antigens, epitope spreading, and gen-
eration of autoimmune responses (Miller et al, 1997).
Multiple sclerosis
It seems appropriate to conclude with some refer-
ence to MS because it was the lack of understand-
ing of the etiology and pathogenesis of this disease
that initiated study of animal models of CNS in-
flammation and demyelination. MS is the most com-
mon human demyelinating disease of the CNS, af-
fecting around 2.5 million people, with an incidence
of 7 per 100,000 per year, a prevalence of 120 per
100,000, and a lifetime risk of 1 in 400 (Compston
and Coles, 2002). Prevalence varies according to ge-
netics, latitude, and other factors, but reaches 300 per
100,000 in areas of Northern Europe. MS is prevalent
amongst Caucasians but rare in Africans or Asians.
Even within areas of high risk, these ethnic popu-
lations are at a lower risk than Caucasians. In most
patients (80%), the disease is characterized by acute
relapses with remissions, followed by a secondary
progressive phase. For 20% of patients, the disease
is progressive from the onset (primary progressive).
Pathologically, MS manifests as acute focal inflam-
matory demyelination, with varying degrees of ax-
onal loss, culminating in development of multifocal
sclerotic plaques. The extent of cellular infiltration
in acute lesions and the degree of oligodendrocyte
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loss is highly heterogeneous and may reflect distinct
pathogenic mechanisms (Lucchinetti et al, 2000).
The etiology of MS remains unknown but involves
the interaction of genetic, immunological, and prob-
ably environmental factors. Although the risk of de-
veloping the disease is significantly higher in family
members of patients with MS (Ebers et al, 1995), ge-
netic predisposition is polygenic (Oksenberg et al,
2001). Among identified susceptibility loci, the
HLA class II alleles DR15 and DQ6 (DRB1*1501
and DQB2*0602) show the strongest association in
Caucasians (Olerup and Hillert, 1991). However, a
concordance rate of only 30% amongst monozygotic
twins indicates the involvement of nongenetic fac-
tors (Ebers et al, 1986). Evidence for an environ-
mental element is suggested by migration studies
wherein movement before adolescence from a high-
risk to a low-risk region reduces the risk of devel-
oping MS (Gale and Martyn, 1995). Equally, several
“MS epidemics,” frequently amongst island popula-
tions, have supported the role for an environmental
agent. Within the Faroe Islands, documented cases
of MS only occurred in the years following the occu-
pation of the Islands by British troops during World
War II (Kurtzke et al, 1993). Associations between
infectious agents and MS, including measles virus
(Field et al, 1972), parainfluenza virus (ter Meulen
et al, 1972), canine distemper (Cook and Dowling,
1977), Chlamydia pneumoniae (Sriram et al, 1999),
Epstein-Barr virus (Ascherio et al, 2001), human her-
pes virus-6 (Challoner et al, 1995) and retroviruses
(Perron et al, 1997), have been reported. Neverthe-
less, to date, no specific environmental agent has been
substantiated as the etiologic agent of this disease.
Whereas the initiating event in the etiology of MS
remains unknown, a role for the immune system in
the pathogenesis is clear. One of the diagnostic mark-
ers for MS is the presence of an intrathecal oligoclonal
IgG response. Clonal expansion of T cells, primarily
of the CD8C phenotype, has been reported in CNS le-
sions (Babbe et al, 2000; Jacobsen et al, 2002). Exacer-
bation of disease following treatment with IFN-° sug-
gests that CD4C T cells with a Th-1 phenotype might
be important in promoting MS (Panitch et al, 1987).
However, in clinical trials, antibodies against CD4C T
cells (van Oosten et al, 1997) or anti-TNFfi antibodies
(van Oosten et al, 1996) fail to ameliorate disease.
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